New CAR T cell therapy targeting BAFF-R for treating acute B-cell leukemia
BAFF-R CAR T cell therapy for ALL
This study is testing a new type of CAR T cell therapy that targets a specific protein in B-cell leukemia to help improve treatment for both kids and adults who haven't responded well to current therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beckman Research Institute/city of Hope NIH-funded |
| Lab location | 1 site (Duarte, United States) |
| Project ID | NIH-11057519 on NIH RePORTER |
What this research studies
This research focuses on developing a novel CAR T cell therapy that targets the B-cell activating factor receptor (BAFF-R) to treat acute B-cell lymphoblastic leukemia (B-ALL). The approach aims to address the challenge of treatment resistance seen in current therapies, particularly in patients who have relapsed or are resistant to existing treatments like CD19-directed CAR T therapy. By utilizing BAFF-R, which is present in B-ALL cells, the therapy seeks to improve outcomes for both children and adults suffering from this aggressive cancer. The research includes preclinical models to evaluate the effectiveness of these CAR T cells against B-ALL, especially in cases where traditional targets are no longer viable.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and adults diagnosed with acute B-cell lymphoblastic leukemia, especially those with relapsed or refractory disease.
Not a fit: Patients with B-ALL who are not eligible for CAR T cell therapy or those with other types of leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with B-ALL, particularly those who have not responded to existing therapies.
How similar studies have performed: While CAR T therapies targeting CD19 and CD22 have shown promise, this approach targeting BAFF-R is novel and has not been extensively tested in clinical settings.
Where this research is happening
Duarte, United States
- Beckman Research Institute/city of Hope — Duarte, United States (Active)
Researchers
- Principal investigator: Kwak, Larry W — Beckman Research Institute/city of Hope
- Study coordinator: Kwak, Larry W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.